ANNEXON INC (ANNX)

US03589W1027 - Common Stock

4.88  +0.22 (+4.72%)

After market: 5.1 +0.22 (+4.51%)

Fundamental Rating

3

Overall ANNX gets a fundamental rating of 3 out of 10. We evaluated ANNX against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANNX as it has an excellent financial health rating, but there are worries on the profitability. ANNX has a expensive valuation and it also scores bad on growth.



1

1. Profitability

1.1 Basic Checks

ANNX had negative earnings in the past year.
In the past year ANNX has reported a negative cash flow from operations.
ANNX had negative earnings in each of the past 5 years.
In the past 5 years ANNX always reported negative operating cash flow.

1.2 Ratios

ANNX has a Return On Assets of -45.10%. This is comparable to the rest of the industry: ANNX outperforms 54.27% of its industry peers.
With a decent Return On Equity value of -53.58%, ANNX is doing good in the industry, outperforming 65.70% of the companies in the same industry.
Industry RankSector Rank
ROA -45.1%
ROE -53.58%
ROIC N/A
ROA(3y)-46.76%
ROA(5y)-47.35%
ROE(3y)-57.06%
ROE(5y)-55.92%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ANNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

ANNX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ANNX has been reduced compared to 5 years ago.
There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.37 indicates that ANNX is not a great score, but indicates only limited risk for bankruptcy at the moment.
ANNX has a better Altman-Z score (2.37) than 72.53% of its industry peers.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.37
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 14.72 indicates that ANNX has no problem at all paying its short term obligations.
ANNX has a Current ratio of 14.72. This is amongst the best in the industry. ANNX outperforms 89.76% of its industry peers.
A Quick Ratio of 14.72 indicates that ANNX has no problem at all paying its short term obligations.
ANNX has a Quick ratio of 14.72. This is amongst the best in the industry. ANNX outperforms 89.76% of its industry peers.
Industry RankSector Rank
Current Ratio 14.72
Quick Ratio 14.72

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.98% over the past year.
EPS 1Y (TTM)37.98%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

ANNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.57%
EPS Next 2Y2.77%
EPS Next 3Y2.94%
EPS Next 5Y23.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

ANNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.77%
EPS Next 3Y2.94%

0

5. Dividend

5.1 Amount

ANNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ANNEXON INC

NASDAQ:ANNX (5/3/2024, 7:00:00 PM)

After market: 5.1 +0.22 (+4.51%)

4.88

+0.22 (+4.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap444.76M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.1%
ROE -53.58%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 14.72
Quick Ratio 14.72
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)37.98%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y